Page last updated: 2024-10-15

lobucavir

Description

lobucavir: inhibits the replication of HIV virus in T cells, monocytes & macrophages in vitro by inhibiting DNA polymerase and viral DNA synthesis [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID135413519
CHEMBL ID23550
SCHEMBL ID51918
SCHEMBL ID15531899
MeSH IDM0175634

Synonyms (62)

Synonym
sq-34514
lobucavir (usan/inn)
D04757
126062-18-8
cyclobut-g
sq-33,054
(+/-)-cyclobut-g
(+/-)-lobucavir
(+/-)-bhcg
9-[1.beta.-2.alpha.-3.beta.]-2,3-bis(hydroxymethyl)-1-cyclobutyl]guanine
sq 33054
2-amino-9-[(1r,2r,3s)-2,3-bis(hydroxymethyl)cyclobutyl]-1h-purin-6-one
(+/-)-9-[2,3-bis(hydroxymethyl)-1-cyclobutyl]guanine
127759-89-1
c-oxt-g
(r)-9-[2,3-bis(hydroxymethyl)-1-cyclobutyl]guanine
c-oxetanocin-g
bms-180194
lobucavir
cygalovir
(+)cyclobut-g
[1r-1.alpha.,2.beta.,3.alpha.]-2-amino-9-[2,3-bis(hydroxymethyl)cyclobutyl]- 6h-purin-6-one
(r)-bhcg
sq 34,514
6h-purin-6-one, 2-amino-9-(2,3-bis(hydroxymethyl)cyclobutyl)-1,9-dihydro-, (1r-(1alpha,2beta,3alpha))-
6h-purin-6-one, 2-amino-9-((1r,2r,3s)-2,3-bis(hydroxymethyl)cyclobutyl)-1,9-dihydro-
9-((1r,2r,3s)-2,3-bis(hydroxymethyl)cyclobutyl)guanine
a-69992
(+)-cyclobut g
6h-purin-6-one, 2-amino-9-(2,3-bis(hydroxymethyl)cyclobutyl)-1,9-dihydro, (1r-(1alpha,2beta,3alpha))
lobucavir [usan:inn]
drg-0235
bms 180194
2-amino-9-(2,3-bis(hydroxymethyl)cyclobutyl)-1,9-dihydro-6h-purin-6-one
sq 34514
carbocyclic oxetanocin g
9-(2,3-bis-(hydroxymethyl)-1-cyclobutyl)guanine
CHEMBL23550
unii-8u5pyq1r2e
(+-)-lobucavir
6h-purin-6-one, 2-amino-9-(2,3-bis(hydroxymethyl)cyclobutyl)-1,9-dihydro-, (1alpha,2beta,3alpha)-(+-)-
6h-purin-6-one, 2-amino-9-((1r,2r,3s)-2,3-bis(hydroxymethyl)cyclobutyl)-1,9-dihydro-, rel-
8u5pyq1r2e ,
ccris 9309
(+-)-cyclobut-g
SCHEMBL51918
lobucavir [who-dd]
9-[(1r,2r,3s)-2,3-bis(hydroxymethyl)cyclobutyl]guanine
lobucavir [usan]
lobucavir [mart.]
6h-purin-6-one, 2-amino-9-(2,3-bis(hydroxymethyl)cyclobutyl)-1,9-dihydro, (1r-(1.alpha.,2.beta.,3.alpha.))
lobucavir [inn]
2-amino-9-((1r,2r,3s)-2,3-bis(hydroxymethyl)cyclobutyl)-1h-purin-6(9h)-one
SCHEMBL15531899
DTXSID40155063
J-005538
2-amino-9-((1r,2r,3s)-2,3-bis(hydroxymethyl)-cyclobutyl)-1h-purin-6(9h)-one
DB12531
lobucavin
Q27271016
A889151
6h-purin-6-one, 2-amino-9-[(1r,2r,3s)-2,3-bis(hydroxymethyl)cyclobutyl]-1,9-dihydro-

Research Excerpts

Overview

Lobucavir (LBV) is a deoxyguanine nucleoside analog with broad-spectrum antiviral activity.

ExcerptReference
"Lobucavir (LBV) is a deoxyguanine nucleoside analog with broad-spectrum antiviral activity. "( Lobucavir is phosphorylated in human cytomegalovirus-infected and -uninfected cells and inhibits the viral DNA polymerase.
Alam, M; Cianci, CW; Colonno, RJ; Sheaffer, AK; Tenney, DJ; Tuomari, AV; Voss, SM; Yamanaka, G, 1997
)

Bioavailability

ExcerptReference
" In mice, SQ 34,514 had an oral bioavailability of 80% based on urinary excretion."( Evaluation of SQ 34,514: pharmacokinetics and efficacy in experimental herpesvirus infections in mice.
Blue, B; Bonner, DP; Braitman, A; Clark, JM; Field, AK; Lynch, JS; Michalik, T; Olsen, SJ; Swerdel, MR; Tuomari, AV, 1991
)
" Interestingly, oral BMS-180194 demonstrated a similar antiviral efficacy as that obtained by the parental route of administration suggesting a high oral bioavailability of the compound."( Efficacy of BMS-180194 against experimental cytomegalovirus infections in immunocompromised mice.
Clark, JM; Drain, RL; Franco, CA; Yang, H, 1996
)
" Valganciclovir, a prodrug of ganciclovir, offers excellent oral bioavailability and is the closest to approval of all the new anti-CMV drugs."( Therapeutic developments in cytomegalovirus retinitis.
Hoffman, VF; Skiest, DJ, 2000
)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID236913Permeability Coefficient in Caco-2 cell culture model2005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
Exploring the role of different drug transport routes in permeability screening.
AID236268Fraction absorbed in human intestine after oral administration compound was measured2005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
Exploring the role of different drug transport routes in permeability screening.
AID236914Permeability Coefficient in hexadecane membranes model2005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
Exploring the role of different drug transport routes in permeability screening.
AID236916Percentage of mass balance in hexadecane membranes model2005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
Exploring the role of different drug transport routes in permeability screening.
AID236912Permeability Coefficient in 2/4/A1 cell model2005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
Exploring the role of different drug transport routes in permeability screening.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (37)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's23 (62.16)18.2507
2000's13 (35.14)29.6817
2010's1 (2.70)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews4 (10.26%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other35 (89.74%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Pilot Study of the Antiviral Activity of Multiple Doses of Oral Lobucavir in AIDS Patients[NCT00002352]30 participants InterventionalCompleted
[information is prepared from clinicaltrials.gov, extracted Sep-2024]
chemdatabank.com